Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
BACKGROUND
Skin toxicity has recently been recognized as a dose-limiting toxicity of antineoplastic therapy.


CONCLUSIONS
We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel.
Susnjar
Snezana
S
Department for Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia. susnjars@ncrc.ac.yu
Bosnjak
Snezana M
SM
Radulovic
Sinisa
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced*
D003841:Deoxycytidine; D000069287:Capecitabine; D017239:Paclitaxel; D005472:Fluorouracil
Oncology. 2004;67(2):117-22
15539915
J BUON. 2007 Apr-Jun;12(2):189-96
17600871
J Clin Oncol. 2004 Jun 15;22(12):2321-7
15197193
Cancer. 2000 May 15;88(10):2367-71
10820360
J Clin Oncol. 2001 Nov 15;19(22):4216-23
11709565
Oncology. 2006;71(1-2):54-60
17344671
Ann Oncol. 1998 Oct;9(10):1139-40
9834830
Eur J Cancer. 2004 Feb;40(3):352-7
14746852
J Clin Oncol. 1999 Jun;17(6):1915-25
10561233
Ann Oncol. 2001 May;12(5):605-14
11432617
Cancer. 2001 Oct 1;92(7):1759-68
11745247
Clin Cancer Res. 1998 Apr;4(4):1013-9
9563897
Ann Oncol. 2003 Oct;14(10):1588-9
14504063
J Clin Oncol. 2002 Nov 1;20(21):4404-5; author reply 4405
12409345
Br J Cancer. 2004 May 4;90(9):1740-6
15150624
Lancet. 2001 Mar 24;357(9260):910
11289346
J Clin Oncol. 2006 Sep 20;24(27):4384-90
16926223
Ann Oncol. 2003 Feb;14(2):333-7
12562663
Ann Oncol. 2006 Jan;17(1):79-84
16284056
J Clin Oncol. 1998 Oct;16(10):3353-61
9779712
Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40
15341880